- How we are supporting the UN Global Plastics Treaty
- India roars ahead of China to top Asian IPO rankings
- Stock Market Today: S&P 500, Dow Jones End 5-Day Losing Streak on Tech Jump
- Will a government shutdown impact the stock market? Experts weigh in
- Stock Market News Today highlights on December 25, 2024 : Indian pharma sector to grow 9-11% in FY26: From Lupin to Max Healthcare—Top 5 stock picks by Motilal Oswal for 2025
As 2024 concludes, the U.S. stock market has experienced a mix of highs and lows, with major indices posting strong annual gains despite a weak finish. In the current market landscape, penny stocks—often representing smaller or newer companies—continue to capture investor interest due to their potential for value and growth. While the term “penny stocks” may seem outdated, these investments can still offer compelling opportunities for those looking beyond large-cap names, especially when backed by solid financials and promising prospects.
You are watching: 3 Promising US Penny Stocks With Market Caps Under $80M
Name | Share Price | Market Cap | Financial Health Rating |
BAB (OTCPK:BABB) | $0.77 | $6.03M | ★★★★★★ |
Inter & Co (NasdaqGS:INTR) | $4.22 | $1.84B | ★★★★☆☆ |
QuantaSing Group (NasdaqGM:QSG) | $3.08 | $111.43M | ★★★★★★ |
Kiora Pharmaceuticals (NasdaqCM:KPRX) | $3.30 | $9.9M | ★★★★★★ |
ZTEST Electronics (OTCPK:ZTST.F) | $0.29 | $10.49M | ★★★★★★ |
CBAK Energy Technology (NasdaqCM:CBAT) | $0.94 | $97.13M | ★★★★★☆ |
Imperial Petroleum (NasdaqCM:IMPP) | $3.01 | $93.12M | ★★★★★★ |
Golden Growers Cooperative (OTCPK:GGRO.U) | $4.50 | $67.38M | ★★★★★★ |
BTCS (NasdaqCM:BTCS) | $2.47 | $43.38M | ★★★★★★ |
Smith Micro Software (NasdaqCM:SMSI) | $1.31 | $24.65M | ★★★★★☆ |
Click here to see the full list of 735 stocks from our US Penny Stocks screener.
See more : What Will The Market Return In 2025?
Let’s review some notable picks from our screened stocks.
Simply Wall St Financial Health Rating: ★★★★★★
Overview: ESSA Pharma Inc. is a clinical-stage pharmaceutical company developing small molecule drugs for prostate cancer treatment, with a market cap of $79.90 million.
Operations: ESSA Pharma Inc. has not reported any revenue segments.
Market Cap: $79.9M
ESSA Pharma Inc., a clinical-stage pharmaceutical company, is currently pre-revenue and focuses on developing prostate cancer treatments. It remains debt-free with substantial short-term assets of US$127.6 million, covering both its short- and long-term liabilities. Despite a seasoned management team, ESSA has faced challenges including increased weekly volatility and unprofitability with growing losses over the past five years. Recent earnings reports showed a net loss of US$28.54 million for 2024, up from the previous year. Additionally, ESSA terminated its Phase 2 trial for masofaniten due to insufficient efficacy compared to standard treatment options.
Simply Wall St Financial Health Rating: ★★★★★★
Overview: VerifyMe, Inc., along with its subsidiaries, offers traceability and customer support services using software and process technology, with a market cap of $8.29 million.
Source link https://finance.yahoo.com/news/3-promising-us-penny-stocks-200816456.html
Source: https://incomestatements.info
Category: News